A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination with Nivolumab in Patients with Relapsed or Refractory Aggressive B-cell Lymphomas

Brief description of study

The purpose of this study is to compare the anti-lymphoma activity and possible side effects of using CDX-1127 (varlilumab) along with another immunotherapy drug, nivolumab. CDX-1127 (varlilumab) is an antibody that can stimulate the immune system to attack cancer tumor cells. Nivolumab is an antibody that can block signals that some types of tumors may use to suppress the immune system.


Clinical Study Identifier: s19-00047
ClinicalTrials.gov Identifier: NCT03038672
Principal Investigator: Catherine M Diefenbach
Currently Recruiting

Contact the research team to learn more about this study.


By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.